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Abstract 
Recurrence and second primary cancer (SPC) continue to represent major obstacles to long-term survival in head and neck 
cancer (HNC). Our aim was to evaluate whether established demographics, lifestyle-related risk factors for HNC and 
clinical data are associated with recurrence and SPC in HNC. We conducted a multicentre study by using data from five 
studies members of the International Head and Neck Cancer Epidemiology consortium—Milan, Rome, Western Europe, 
Sao Paulo, and Japan, totalling 4005 HNC cases with a median age of 59 (interquartile range 52–67). Multivariate hazard 
ratios (HRs) and 95% confidence intervals (CIs) were estimated for recurrence and SPC. During follow-up, 1161 (29%) 
patients had recurrence and 343 (8.6%) developed SPC. Advanced tumour stage was associated with increased risk of 
recurrence in HNC overall (HR = 1.76, 95% CI 1.41–2.19). Women with laryngeal cancer had a reduced risk of recurrence 
compared to men (HR = 0.39, 95% CI: 0.24–0.74). Concerning predictors of SPC, advanced age (HR = 1.02; 95% CI: 
1.00–1.04) and alcohol consumption ([ 1 drink per day, HR = 2.11; 95% CI: 1.13–3.94) increased the risk of SPC among 
patients with laryngeal cancer. Additionally, women were at higher risk of SPC, in HNC overall group (HR = 1.68; 95% 
CI: 1.13–2.51) and oropharyngeal cancer group (HR = 1.74; 95% CI: 1.02–2.98). Tumour stage and male gender (larynx 
only) were positive predictors of cancer recurrence in HNC patients. Predictors of SPC were advanced age and alcohol use 
among laryngeal cancer cases, and female gender for oropharyngeal and HNC overall. 
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 Introduction 
 
Head and neck cancer (HNC) is the sixth most common cancer in men and the 13th in women worldwide, with 195,000 new 
cases estimated in the South-East Asia Region, 148,000 in the European Region and 101,000 in the Region of the Americas 
in 2012. These regions account for about three-fourths of worldwide HNC cases [1]. 
Following diagnosis of HNC, 5-year relative survival var- ies substantially across countries [2–4]. In Europe, five- year 
age-standardised relative survival is the highest for laryngeal cancer and the poorest for hypopharyngeal can- cer: 59% for 
larynx, 45% for oral cavity, 39% for oropharynx, and 25% for hypopharynx. For those surviving the first year, the 5-year 
conditional survival probability increases to 71% for larynx, 62% for oral cavity, 58% for oropharynx and 41% for 
hypopharynx [3]. 
Recurrent disease and second primary cancer (SPC) continue to represent the major obstacles to long-term sur- vival in 
HNC [6, 7]. Despite advances in the treatment of HNC, it is currently well established that the percentage of patients who 
will develop recurrent disease can be as high as 50% [8]. HNC survivors also have an increased risk of developing SPC 
compared to the overall population, with frequent SPC of the head and neck, oesophagus, and lung, which are tobacco- 
and alcohol-related cancers [6]. The incidence of SPC varies substantially across several studies, depending mainly on the 
follow-up time and systematic screening of patients with HNC [6]. A multicentre study from 13 population-based 
cancer registries in Europe, Canada, Australia, and Singapore, including 99,257 patients who were diagnosed with a first 
HNC between 1943 and 2000 found a proportion of SPC development of 10.9% [9]. So far, a few large studies evaluated 
whether established demographics and lifestyle-related risk factors for HNC influence recurrence, and development of 
SPC in HNC patients. To explore these issues, we conducted a multi- centre study by using data from studies 
conducted in Brazil, Italy, and Japan, which are members of the Inter- national Head and Neck Cancer
 Epidemiology (INHANCE) Consortium, totalling 4005 HNC cases. 
Methods 
Study population 
 
We included patients 18 years and older with histologically confirmed primary squamous cell carcinoma of the head and 
neck arising in the four major anatomical sites of the oral cavity, oropharynx, hypopharynx, and larynx. Patients with 
primary cancers outside these four anatomical sites, patients with a history of previous cancers, and with incomplete data or 
follow-up were excluded. Participants were selected from five referent studies within the INHANCE Consortium [10]: 
Milan (Italy), Rome (Italy), Western Europe involving three Italian centres [Aviano (Friuli Venezia Giulia), Padua (Veneto), 
Turin (Pie- monte)], Sao Paulo (Brazil), and Nagoya (Japan). 
The study was approved by the local Ethical Commit- tees at each participating centre and written informed consents 
were obtained from all study subjects. The recruitment period started in 2001 for Nagoya, 2002 for Aviano, Milan, Padua, 
Rome, and Sao Paulo, and ended in 2005 for Aviano, Padua, Turin and Japan, 2009 for Milan, and 2014 for Rome and Sao 
Paulo. A total of 4005 eligible subjects were included in the analysis of recurrence, while 3982 subjects were considered for 
the analysis of SPC. 
 
Data collection 
 
Patients were interviewed face-to-face in all centres by trained interviewers or medical doctors using a structured and vali- 
dated questionnaire. All patients were evaluated for gender, age, ethnicity, education level, site of primary tumour, tumour, 
node, metastasis (TNM) stage, treatment characteristics, comorbidity and smoking and alcohol con- sumption. Information 
on alcohol and smoking habits con- sidered the time period ending 1 year prior to HNC diagnosis. These data were pooled and 
managed by the INHANCE consortium coordinator. Data on tumour pathology, treatment characteristics, cancer recurrence 
and SPC were obtained from medical records and cancer registries. Different study centres used different cancer codes, 
which were converted into International Classification of Diseases for Oncology (ICD-O-2) when included into this study. 
All cases of first primary HNCs were followed up for cancer recurrence and/or SPC from the date of initial head and 
neck cancer diagnosis to the date of event, end of follow-up, or loss to follow-up, whichever occurred first. Death 
certificate data were used to track the cause of death which was coded according to the ICD, Ninth Revision. All the data 
from participating centres were collected by the project team at the Universita` Cattolica del Sacro Cuore in Rome and were 
cleaned and checked for internal consis- tency. Clarifications were requested from the original investigators when needed. 
 
Study variables and outcomes definition 
 
 HNCs were classified according to the following anatomic sites using the ICD-O-2 codes: oral cavity (C00.3–C00.9, 
C02.0–C02.3, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C06.0–C06.2, C06.8, and C06.9), orophar- ynx  
(C01.9,  C02.4,  C05.1,  C05.2,  C09.0,  C09.1, C09.8, 
C09.9, C10.0–C10.4, C10.8, and C10.9), hypopharynx (C12.9, C13.0–C13.2, C13.8, and C13.9), oral cavity or pharynx 
overlapping or not otherwise specified (C02.8, C02.9,  C05.8,  C05.9,  C14.0,  C14.2,  and  C14.8), larynx 
(codes C32.0–C32.3 and C32.8–C32.9). Cancers were staged according to the TNM Staging System [11]. Index cancer 
stage was then dichotomized into early stage (in- cluding I and II clinical stage) and late stage (III and IV). We also 
clustered treatment into five categories: surgery only; surgery with radiation; radiation and/or chemother- apy; surgery plus 
radiation and/or chemotherapy; and  other. Education data were classified into three strata: college graduate, high-technical 
school graduate and less than high school depending on the level of formal educa- tion of participants. Patients were 
categorized as never, former, or current smokers or missing in case that the information was not available. Cumulative 
tobacco con- sumption was calculated as intensity of smoking (never smokers, 20 or less cigarettes/day, [ 20 
cigarettes/day), and smoking  duration  in  years  (never  smokers,  B 20,  [ 20 years). Regarding the alcohol drinking 
status, sub- jects were classified as never, former and current drinkers, and according to the intensity of use as never 
drinkers, those  who  had B 1  drink  equivalent/day,  and  those with [ 1 drinks/day. Former users were defined as 
those who quit cigarette smoking or alcohol consumption for 1 or more years prior to the tumour diagnosis. 
Cancer recurrence was defined as local, regional or distant return of cancer of the same histologic type, usually after a 
period of time during which the cancer could not be detected and after that the patient was defined as disease free. SPC was 
defined by the criteria of Warren and Gates 
[12] in the Italian participating centres, where second tumour had to be different in histopathologic type, or in case of the 
same type to be clearly separated by more than 2 cm of normal epithelium, or occurring more than 3 years after the 
treatment for the primary tumour. In the Japanese study, SPC was defined as a metachronous invasive solid cancer 
developing C 6 months after an index HNC. If the second cancer was of different histopathologic type, or if it developed in a 
different location, it was coded as a SPC. If the second cancer was histopathologically the same and developed in the same 
region as the index cancer, it was only coded as a SPC if greater than 60 months had passed since the index diagnosis. The 
Brazilian study considered SPC as a new tumour diagnosed after a primary, in another location and confirmed by anatomical 
exam. In all partic- ipating studies, SPC was needed to be pathologically confirmed as distinct malignancy, with the 
possibility of metastatic tumour being excluded. 
 
Statistical analysis 
 
Descriptive analyses were conducted to describe the study population by demographic and known HNC risk factors. The 
survival after initial tumour development was set as the time interval from the diagnosis of the index tumour to most recent 
follow-up or the patient’s death. The survival rate was calculated with the Kaplan–Meier method, which was also used to 
plot the survival curves. 
The impact of predictor variables on cancer recurrence and development of SPC was determined using univariate and 
multivariate analyses. In the initial univariate analyses, epidemiological variables included age in years, ethnicity, sex, body 
mass index (BMI), education, and smoking and alcohol status, while clinical characteristics included tumour site, stage, and 
presence of comorbidity. A multi- variable proportional hazards model was set up by including the variables that reported a 
prognostic potential in the univariate analysis (p \ 0.1). The Cox’s proportional hazards model was used to determine 
independent predic- tors of cancer recurrence and SPC. We used Schoenfeld residuals to formally test the Cox proportional 
hazards assumption for each covariate [13]. Analyses were per- formed for overall HNC and for separate subsite (oral cavity, 
oropharynx, hypopharynx and larynx) where pos- sible, and statistical significance was set at p \ 0.05. We also restricted 
our study population for the SPC analyses, to the patients with follow-up of at least two years, since it has been reported that 
the interval between the index and the second tumour ranges from 2 to 4 years [14, 15]. All statistical analyses were 
performed using Stata software (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp 
LP). 
 
Results 
 
We included a total of 4005 HNC cases in the recurrence analysis and 3982 cases in the SPC analysis from five studies 
within the INHANCE consortium (Table 1). The majority of the patients were from Brazil, both for the recurrence (70.7%) 
and the SPC (70.8%) analysis, then from Italy–Rome, Milan, Aviano, Padua and Turin (21.9% for the recurrence, and 
21.8% for SPC), and finally from Japan (7.3 and 7.4% of the cases in recurrence and SPC analyses, respectively). 
The recurrence analysis included 1351 (36.0%) patients with oral cavity cancer, 1249 (33.3%) laryngeal cancer, 799 
 (21.3%) oropharyngeal cancer, 356 (9.5%) hypopha- ryngeal cancer, and 250 (6.2%) patients with oral cavity or pharynx 
not otherwise specified cancer. SPC analysis included 1340 (35.9%) patients with oral cavity cancer, 1244 (33.3%) 
laryngeal cancer, 795 (21.3%) oropharyngeal cancer, 356 (9.5%) hypopharyngeal cancer and the rest of the patients (6.2%) 
with oral cavity or pharynx not other- wise specified cancer. Median follow up time for cases included in the recurrence 
analysis was 21 (IQR 9–55) months, ranged from 17 (IQR 8–40) months in Sao Paulo to 88 (IQR 53–99) months in 
Aviano. During the follow- up, 1161 (29.0%) patients had cancer recurrence. When looking at the location of primary 
cancer, during the fol- low-up 117 (32.9%) hypopharyngeal cancer patients had a recurrence, 423 (31.3%) oral cancer 
patients, 244 (30.5%) 
oropharyngeal cancer patients, 296 (23.7%) laryngeal cancer patients and 81 (32.4%) oral cavity or pharynx not otherwise 
specified cancer cases. 
Regarding the 3982 patients included in SPC analysis, median follow-up time was 26 (IQR 11–59) months, from 20 
(IQR 10–44) months in the Sao Paulo study to 82 (IQR 31–98) months in Aviano, during which 343 (8.6%) patients 
developed an SPC. Around 10% of patients with primary laryngeal cancer had SPC, 8.1% of patients with oral cavity 
cancer, 7.7 and 7.6% with oropharynx and hypopharynx cancer, respectively, and 8.5% of patients with oral cavity or 
pharynx not otherwise specified cancer developed an SPC (Table 2). 
When considering all HNC sites, recurrence-free 5-year survival was 5.90% (standard deviation (SD) = 0.24): oral cavity 
6.95% (SD = 0.25), oropharynx 7.30% (SD = 0.26), hypopharynx 3.92% (SD = 0.2), and larynx 4.8% (SD = 0.21) (Fig. 1). 
On the other hand, SPC-free 5-year survival was 5.97% (SD = 0.24) for all HNC combined,  8.56%  (SD = 0.28) for oral 
cavity, 5.92% (SD = 0.24) orophar- ynx, 4.92% (SD = 0.22)  for  hypopharynx  and  4.25%  (SD = 0.20) for laryngeal cancer 
(Figure not shown). We further explored the differences in survival by cancer type and for the analysis of the second primary 
no survival curve was statistically different from the others, while for the recurrence analysis only larynx cancer had a 
statisti- cally greater survival (p \ 0.001). 
 
Table 1 Characteristics of head and neck cancer cases from 5 studies participating in the international head and neck cancer epidemiology 
(INHANCE) Consortium, according to tumour site 
INHANCE studies Recruitment period Oral cavity Oropharynx Hypopharynx Larynx OC, OP, HP NOS Total 
      
n %a n %a n %a n %a n % n %b 
4005 cases included in recurrence analysis 
 
Milan, Italy 2002–2009 19 16.2 7 6.0 7 6.0 84 71.8 3 2.5 120 3.0
Rome, Italy 
Western Europe 
2002–2014 79 18.5 73 17.1 18 4.2 256 60.1 5 1.2 431 10.8
Aviano 2002–2005 40 38.1 32 30.5 8 7.6 25 23.8 2 1.9 107 2.7
Padua 2002–2005 24 22.0 24 22.0 14 12.8 47 43.1 1 0.9 110 2.7
Turin 2003–2005 47 43.9 22 20.6 7 6.5 31 29.0 3 2.7 110 2.7
Sao Paulo, Brazil 2002–2014 995 38.3 592 22.8 255 9.8 755 29.1 236 8.3 2833 70.7
Japan 2001–2005 147 50.0 49 16.7 47 16.0 51 17.3 0 0.0 294 7.3
Total  1351 36.0 799 21.3 356 9.5 1249 33.3 250 6.2 4005 100.0
3982 cases included in second primary cancer analysis 
Milan, Italy 2002–2009 19 16.2 7 6.0 7 6.0 84 71.8 3 2.5 120 3.0
Rome, Italy 2002–2014 76 18.4 72 17.4 20 4.8 246 59.4 4 1.0 418 10.5
Western Europe              
Aviano 2002–2005 42 37.8 34 30.6 9 8.1 26 23.4 2 1.8 113 2.8
Padua 2002–2005 25 21.7 25 21.7 14 12.2 51 44.3 1 0.9 116 2.9
Turin 2003–2005 44 43.6 21 20.8 5 5.0 31 30.7 2 1.9 103 2.6
Sao Paulo, Brazil 2002–2014 987 38.2 587 22.7 254 9.8 755 29.2 235 8.3 2818 70.8
Japan 2001–2005 147 50.0 49 16.7 47 16.0 51 17.3 0 nc 294 7.4
Total  1340 35.9 795 21.3 356 9.5 1244 33.3 247 6.2 3982 100.0
OC oral cavity, OP oropharynx, HP hypopharynx, NOS not otherwise specified, nc not computable 
aErcentages were calculated excluding OC, OP, HP NOS 
bColumn percentages 
 
 
 Predictors of the cancer recurrence 
 
Distributions of the selected covariates and adjusted HRs for cancer recurrence by tumour site and considering HNC overall are 
presented in Table 3. Median age of patients included in the analysis was 59 years (IQR 52–67) with  higher prevalence of males 
(77.8%), Caucasians (71.9%), normal BMI (57.8%) and low education level (less than  high-school, 80.3%). Females with laryngeal 
cancer had a reduced risk of cancer recurrence (HR = 0.39, 95% CI 0.24–0.74). Tumour stage IV was associated with an increased 
risk of recurrence in HNC overall (HR = 1.76, 95% CI 1.41–2.19), oral cavity cancer patients (HR = 1.85, 95% CI 1.31–2.61), and 
oropharyngeal cancer (HR = 2.56, 95% CI 1.19–5.51), while tumour stage III showed to have higher risk of recurrence only in HNC 
overall (HR = 1.29, 95% CI 1.00–1.67). Exploring the lifestyle habits in detail, we found that patients with oral cavity cancer that 
were former alcohol consumers had a lower risk of cancer recurrence (HR = 0.64, 95% CI 0.44–0.95) while current consumers with 
hypopharyngeal cancer had an increased risk (HR = 3.43; 95% CI 1.05–11.26). No further signifi- cant association was reported for 
alcohol drinking and smoking habits. 
 
Predictors of the second primary cancer 
 
There were 3081 (77.6%) men and 889 (22.4%) women included in the SPC analysis, with a median age at diag- nosis of 59 (IQR, 
52–67) years, predominantly Caucasians (71.9%), normal BMI (57.7%) and with low educational level (less than high school, 
80.3%). Table 4 presents distribution for the selected covariates and adjusted HRs for SPC by different HNC sites and combined. 
Female gender was found to increase the risk of developing SPC for those with oropharyngeal cancer (HR = 1.74; 95% CI: 1.02–
2.98)   and   HNC    overall    (HR = 1.68;   95%   CI: 1.13–2.51). Advanced age also increased the risk of SPC development for 
patients with laryngeal cancer (HR =  1.02; 95% CI: 1.00–1.04). We found lower risk of developing SPC for Asian ethnic group for 
those with hypopharyngeal   (HR  =  0.12;   95%   CI   0.02–0.91) and laryngeal cancer (HR = 0.04; 95% CI 0.01–0.38). Associ- 
ation was not found for the lifestyle-related risk factors, except the higher risk for those with laryngeal cancer that consumed more 
than one drink per day (HR = 2.11; 95% CI: 1.13–3.94). 
 
Table 2 Median survival time and number of cancer recurrences and second primary cancer by tumour site and study 
1Q first quartile, 3Q third quartile, OC oral cavity, OP oropharynx, HP hypopharynx, NOS not otherwise specified 
 
Cases included in recurrence analysis (n = 4005) Cases included in second primary cancer analysis (n = 3982) 
  
n Follow-up time (months) Recurrence n Follow-up time (months) Second primary cancer 
n 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Median 1Q 3Q   %  Median 1Q 3Q  n % 
Tumour site               
Oral cavity 1351 19 8 50  423 31.3 1340 24 12 55  108 8.1 
Oropharynx 799 15 7 40  244 30.5 795 18 9 50  61 7.7 
Hypopharynx 356 15 7 34  117 32.9 356 20 10 46  27 7.6 
Larynx 1249 30 12 66  296 23.7 1244 37 15 69  126 10.1 
OC, OP, HP NOS 250 21 7 63   81 32.4 247 25 10 64  21 8.5 
INHANCE studies               
Milan, Italy 120 50 17 77 20 16.7 120 49 17 79 21 17.5 
Rome, Italy 431 27 10 63 169 39.2 418 45 17 82 53 12.7 
Western Europe             
Aviano 107 88 53 99 21 19.6 113 82 31 98 23 20.4 
Padua 110 35 12 96 49 44.5 116 28 8 92 43 37.1 
Turin 110 53 11 96 41 37.3 103 60 15 99 18 17.5 
Sao Paulo, Brazil 2833 17 8 40 767 27.1 2818 20 10 44 172 6.1 
Japan 294 51 14 69 94 32.0 294 59 36 74 13 4.4 
Total 4005 21 9 55 1161 29.0 3982 26 11 59 343 8.6 
  
Exploring the same predictors but considering the specific location of SPC (HNC, lung or other) indepen- dently from the type of primary 
HNC, we included a total of 4021 patients with HNC into this analysis, of whom 113 (32.8%) had HN SPC, 54 (15.7%) had lung SPC and 
82 (23.8%) had an SPC in other location, while 95 (27.6%) had no information of SPC site location (Table 5). Analysis also included 39 
patients with missing information on primary HNC site, of whom one patient had SPC. They were not considered for the SPC analysis  
reported  in Table 4. Female gender was associated with higher risk of developing a HN SPC (HR = 1.54; 95% CI 1.01–2.35), as well as 
lung SPC (HR = 4.29; 95% CI 2.24–8.23) and  other location SPC (HR = 1.88; 95% CI: 1.13–3.13). Eth- nicity and education were found 
to be associated with lower risk of SPC. We found lower risk for college/high school graduate (HR = 0.59; 95% CI 0.39–0.82) when all 
cancer sites were combined. Further lower risk for the development of HN SPC was reported for those college/ high school graduates (HR 
= 0.49; 95% CI 0.27–0.91), as well as for patients with Asian ethnicity for the develop- ment of other location SPC (HR = 0.11; 95% CI 
0.01–0.78). Presence of comorbidity was associated with a higher risk of lung SPC (HR = 3.68; 95% CI 1.04–13.02). Alcohol drinking 
was found to be associated with an increased risk of developing a HN SPC (former drinking status,  HR  =  3.87;  95%  CI  1.78–8.44;  
current drinking status, HR  =  2.24; 95% CI 1.06–4.74;  B 1 drinks per day, HR = 6.64, 95% CI 2.37–18.62; [ 1 drinks per day 
HR = 5.78, 95% CI 1.94–17.25), lung SPC ([ 1 drinks per day, HR = 3.38, 95% CI 1.29–8.84), and also for  other SPC  (B 1 drinks  per 
day,  HR = 2.47, 95%  CI 1.00–6.11;[ 1 drinks per day HR = 2.88, 95% CI 1.21–6.87). On the other hand, only current smokers had an 
increased risk of SPC when all SPC sites were combined (HR = 1.57; 95% CI 1.01–2.44) (Table 5). 
We also calculated the HRs for the development of SPC after restricting the sample to patients with follow up of at least two years, 
and found that age was associated with an increased risk of SPC in oral cavity HNC (HR = 1.02, 95% CI 1.00–1.05), drinking status 
increased the risk in laryn- geal cancer (former drinking status, HR = 2.82, 95% CI 1.10–7.23) and all HNC sites combined (HR = 
2.08, 95% CI 1.13–3.85). The amount of alcohol consumed was associated with the higher risk of developing SPC in HNC (B 1 
drinks per day, HR = 3.02, 95% CI 1.27–7.12; [ 1 drinks per day, HR = 2.76, 95% CI 1.10–6.92) (data not shown). 
 
  
 
Table 3 Multivariate predictors of cancer recurrence among 4005 head and neck cancer (HNC) cases by tumor site 
 
Subjectsa  Oral cavityb (TOT/ 
recurrence) 
 Oropharynxb (TOT/ 
recurrence) 
 Hypopharynxb (TOT/ 
recurrence) 
 Larynxc (TOT/ 
recurrence) 
 Totald,e (TOT/ 
recurrence) 
  n = 1351/423  n = 799/244  n = 356/117  n = 1249/296  n = 4005/1161 
 
n %  HR 95% CI  HR 95% CI  HR 95% CI  HR 95% CI  HR 95% CI 
Demographics 
Age at diagnosis 
 
3990 59 (52–67)h 
  
 
1.00 0.99–1.01 
  
 
1.01 0.99–1.02 
  
 
1.00 0.97–1.02 
  
 
1.00 0.98–1.01 
  
 
1.00 0.99–1.01 
Missing 
Gender 
15 0.4           
Men 3104 77.8 1.00  1.00  1.00  1.00  1.00  
Women 887 22.2 0.98 0.76–1.25 0.89 0.63–1.26 1.28 0.75–2.18 0.39 0.24–0.74 0.90 0.76–1.08 
Missing 14 0.3           
BMI                  
Underweight 192 6.6 1.00  1.00  1.00  1.00  1.00  
Normal range 1679 57.8 0.85 0.54–1.34 1.20 0.60–2.38 0.67 0.26–1.72 1.50 0.65–3.44 0.98 0.71–1.34 
Overweight 792 27.3 0.87 0.53–1.41 0.81 0.38–1.73 0.33 0.10–1.04 1.45 0.61–3.43 0.86 0.61–1.20 
Obese 243 8.4 0.75 0.41–1.38 0.52 0.18–1.57 0.33 0.10–1.04 1.74 0.68–4.50 0.88 0.59–1.32 
Missing 1099 27.4           
Ethnicity             
Caucasian 2830 71.9 1.00  1.00  1.00  1.00  1.00  
Black 236 6.0 0.84 0.55–1.29 0.88 0.43–1.81 0.75 0.23–2.44 0.71 0.34–1.45 0.84 0.61–1.14 
Asian 316 8.0 0.84 0.61–1.15 0.67 0.38–1.20 1.64 0.99–2.72 0.40 0.14–1.10 0.81 0.53–1.25 
Other 556 14.1 0.84 0.60–1.17 1.38 0.94–2.03 0.92 0.44–1.91 0.59 0.37–0.95 0.89 0.73–1.10 
Missing 67 1.7           
Education             
Less than high school 2680 80.3 1.00  1.00  1.00  1.00  1.00  
College/high school graduate 657 19.7 1.16 0.98–1.38 0.73 0.49–1.11 0.74 0.39–1.41 1.36 0.99–1.87 1.19 1.00–1.41 
Missing 668 16.7           
Tumour characteristics                  
Stage             
I 430 12.9 1.00  1.00  1.00  1.00  1.00  
II 519 15.6 1.22 0.83–1.80 1.62 0.69–3.85 5.20 0.58–46.79 1.09 0.70–1.68 1.24 0.96–1.61 
III 561 16.9 1.42 0.95–2.12 2.23 0.99–5.06 2.05 0.27–15.83 1.03 0.66–1.59 1.29 1.00–1.67 
IV 1817 54.6 1.85 1.31–2.61 2.56 1.19–5.51 2.81 0.39–20.57 1.37 0.95–1.98 1.76 1.41–2.19 
Missing 678 16.9           
Comorbidity             
No 434 52.1 1.00  1.00  1.00  1.00  1.00  
Yes 399 47.9 1.03 0.61–1.75 1.23 0.62–2.45 0.31 0.10–1.04 1.19 0.69–2.05 1.01 0.74–1.37 
Missing 3172 79.2           
Cigarette smoking                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
  
Table 3 (continued)  
 Subjectsa  Oral cavityb (TOT/recurrence)  Oropharynxb (TOT/recurrence)  Hypopharynxb (TOT/recurrence) Larynxc (TOT/recurrence)  Totald,e (TOT/recurrence) 
   n = 1351/423  n = 799/244  n = 356/117  n = 1249/296  n = 4005/1161 
 n %  HR 95% CI  HR 95% CI  HR 95% CI  HR 95% CI  HR 95% CI 
Smoking status            
Never 383 9.8  1.00  1.00  1.00  1.00  1.00 
Former 965 24.7  0.72 0.50–1.03  1.16 0.62–2.15  1.15 0.44–3.01  1.37 0.71–2.65  0.87 0.68–1.12 
Current 2566 65.6  0.87 0.64–1.18  1.30 0.73–2.31  0.79 0.31–2.04  1.09 0.57–2.08  0.82 0.65–1.04 
Missing 91 2.3           
Years of smoking            
Never smokers 383 10.0  1.00  1.00  1.00  1.00  1.00 
B 20 384 10.0  0.67 0.41–1.12  1.31 0.66–2.60  0.87 0.28–2.66  1.34 0.65–2.80  0.81 0.60–1.09 
[ 20 3060 80.0  0.82 0.57–1.18  1.25 0.71–2.20  0.92 0.36–2.34  1.14 0.60–2.16  0.84 0.67–1.06 
Missing 178 4.4           
Cigarettes per day            
Never smokers 383 10.0  1.00  1.00  1.00  1.00  1.00 
B 20 2430 63.3  0.72 0.59–1.04  1.25 0.71–2.23  0.84 0.33–2.15  1.14 0.60–2.18  0.79 0.63–1.00 
[ 20 1024 26.7  1.15 0.82–1.62  1.22 0.66–2.23  1.07 0.41–2.83  1.27 0.66–2.45  0.96 0.75–1.22 
Missing 168 4.2           
Alcohol drinking 
Drinking status 
Never drinkers 553 14.1 1.00  1.00  1.00  1.00  1.00  
Former 995 25.3 0.64 0.44–0.95 0.99 0.58–1.69 2.45 0.73–8.30 0.98 0.60–1.60 0.88 0.69–1.11 
Current 2380 60.6 0.82 0.67–1.27 1.03 0.63–1.69 3.43 1.05–11.26 1.34 0.89–2.02 1.15 0.94–1.41 
Missing 77 1.9           
Drinks per day             
Never drinkers 553 15.0 1.00  1.00  1.00  1.00  1.00  
B 1 2249 61.1 0.73 0.52–1.02 1.01 0.61–1.68 2.77 0.82–9.39 1.20 0.78–1.85 0.74 0.46–1.09 
[ 1 877 23.8 1.12 0.79–1.60 1.02 0.60–1.74 3.03 0.89–10.27 1.27 0.82–1.96 0.73 0.49–1.07 
Missing 326 8.1           
Text in bold indicates statistically significant risk factors 
CI confidence interval, HNC head and neck cancer, HR hazard ratio, HP hypopharynx, nc not computable, NOS not otherwise specified, OC oral cavity, OP oropharynx 
aNumber of subject and percentages is referred to all HNC sites together 
bHR adjusted by age at diagnosis, gender and stage 
cHR adjusted by age at diagnosis, gender, stage, ethnicity and study centre 
dHR adjusted by age at diagnosis, gender, stage, alcohol drinking status and study centre 
eTotal number includes 250 OC, OP, HP NOS primary HNC with 81 cancer recurrence 
hMedian, interquartile range 
  
 
 
 
Table 4 Multivariate predictors of second primary cancer among 3982 head and neck cancer (HNC) cases by tumor site 
Subjectsa Oral Cavityb (TOT/second 
primary) 
Oropharynxc (TOT/second 
primary) 
Hypopharynxc (TOT/second 
primary) 
Larynxd (TOT/second 
primary) 
Totale,f (TOT/second 
primary) 
 
     
n = 1340/108 n = 795/61 n = 356/27 n = 1244/126 n = 3982/343 
 
 n %  HR 95% CI  HR 95% CI  HR 95% CI  HR 95% CI  HR 95% CI 
Demographics 
Age at diagnosis 
 
 
3969 
 
59 (52–67)g
  
 
1.01 
 
 
0.97–1.06 
  
 
1.01 
 
 
0.99–1.04 
  
 
0.98 
 
 
0.94–1.02 
  
 
1.02 
 
 
1.00–1.04 
  
 
1.00 
 
 
0.98–1.02 
Missing 
Gender 
13 0.3                
Men 3081 77.6 1.00  1.00  1.00  1.00  1.00  
Women 889 22.4 1.70 0.67–4.30 1.74 1.02–2.98 1.13 0.45–2.84 1.41 0.89–2.22 1.68 1.13–2.51 
Missing 12 0.3           
BMI                  
Underweight 190 6.6 1.00  1.00  1.00  1.00  1.00  
Normal range 1660 57.7 0.28 0.02–4.83 0.81 0.18–3.58 0.30 0.04–2.65 0.70 0.21–2.31 1.66 0.21–13.44 
Overweight 788 27.4 nc nc 1.00 0.21–4.66 0.83 0.09–7.38 0.62 0.18–2.18 1.08 0.11–10.76 
Obese 241 8.4 1.45 0.07–28.14 0.63 0.09–4.52 1.34 0.08–22.14 0.44 0.09–2.23 1.60 0.14–18.17 
Missing 1103 27.7           
Ethnicity             
Caucasian 2815 71.9 1.00  1.00  1.00  1.00  1.00  
Black 235 6.0 nc nc 0.40 0.05–2.92 0.66 0.09–5.01 nc nc nc nc 
Asian 316 8.1 nc nc 0.29 0.07–1.18 0.12 0.02–0.91 0.04 0.01–0.38 nc nc 
Other 550 14.0 1.12 0.13–9.40 0.40 0.12–1.30 0.67 0.19–2.35 0.75 0.32–1.76 1.05 0.29–3.77 
Missing 66 1.7           
Education             
Less than high school 2665 80.3 1.00  1.00  1.00  1.00  1.00  
College/high school graduate 653 19.7 0.46 0.10–2.09 0.46 0.20–1.03 0.71 0.24–12.10 0.68 0.41–1.13 0.60 0.35–1.03 
Missing 663 16.6           
Tumour characteristics                  
Stage             
I–II 933 28.3 1.00  1.00  1.00  1.00  1.00  
III–IV 2367 71.7 2.74 0.97–7.75 1.13 0.57–2.23 nc nc 0.88 0.55–1.38 1.17 0.72–1.91 
Missing 682 17.1           
Comorbidity             
No 428 51.8 1.00  1.00  1.00  1.00  1.00  
Yes 398 48.2 2.38 0.87–6.51 1.09 0.40–2.93 0.20 0.03–1.26 1.13 0.63–2.03 1.14 0.75–1.73 
Missing 3156 79.3           
Cigarette smoking 
Smoking status 
                 
Never 386    9.9 1.00 1.00 1.00 1.00 1.00 
  
 
 
 
Table 4 (continued)  
 Subjectsa  Oral Cavityb (TOT/second 
primary) 
 Oropharynxc (TOT/second 
primary) 
 Hypopharynxc (TOT/second 
primary) 
 Larynxd (TOT/second 
primary) 
 Totale,f (TOT/second 
primary) 
   n = 1340/108  n = 795/61  n = 356/27  n = 1244/126  n = 3982/343 
 n %  HR 95% CI  HR 95% CI  HR 95% CI  HR 95% CI  HR 95% CI 
Former 952 24.5  1.00 0.27–3.65  0.87 0.33–2.28  0.84 0.16–4.43  1.04 0.43–2.53  0.63 0.33–1.19 
Current 2554 65.6  1.84 0.52–6.48  1.30 0.57–3.00  0.80 0.17–3.71  1.75 0.75–4.07  1.22 0.67–2.20 
Missing 90 2.3           
Years of smoking            
Never smokers 386 10.1  1.00  1.00  1.00  1.00  1.00 
B 20 382 10.0  nc nc  0.79 0.23–2.75  0.36 0.03–4.15  0.83 0.28–2.50  0.41 0.15–1.12 
[ 20 3039 79.8  1.59 0.54–4.71  1.23 0.54–2.79  0.87 0.19–3.99  1.54 0.67–3.55  1.00 0.58–1.75 
Missing 175 4.4           
Cigarettes per day            
Never smokers 386 10.1  1.00  1.00  1.00  1.00  1.00 
B 20 2423 63.5  1.44 0.46–4.47  1.24 0.54–2.85  0.90 0.19–4.19  1.32 0.57–3.07  0.83 0.47–1.48 
[ 20 1005 26.4  1.22 0.27–5.48  1.00 0.39–2.53  0.60 0.11–3.28  1.74 0.73–4.15  1.12 0.61–2.08 
Missing 168 4.2           
Alcohol drinking 
Drinking status 
Never drinkers 548 14.0 1.00  1.00  1.00  1.00  1.00  
Former 996 25.5 8.15 0.87–76.28 1.01 0.38–2.65 1.59 0.33–7.80 1.16 0.44–3.06 1.23 0.55–2.73 
Current 2362 60.5 5.07 0.62–41.32 1.44 0.63–3.29 1.09 0.23–5.09 1.19 0.46–3.12 1.30 0.67–2.53 
Missing 76 1.9           
Drinks per day             
Never drinkers 548 15.0 1.00  1.00  1.00  1.00  1.00  
B 1 2240 61.2 4.42 0.45–43.34 1.08 0.44–2.63 0.77 0.15–3.83 1.58 0.82–3.05 0.65 0.19–2.25 
[ 1 870 23.8 6.14 0.75–49.99 1.54 0.66–3.62 1.48 0.31–7.15 2.11 1.13–3.94 1.12 0.33–3.75 
Missing 324 8.1           
Text in bold indicates statistically significant risk factors 
CI confidence interval, HNC head and neck cancer, HR hazard ratio, HP hypopharynx, nc not computable, NOS not otherwise specified, OC oral cavity, OP oropharynx 
aNumber of subject and percentages is referred to all HNC sites together 
bHR adjusted by age at diagnosis, gender, stage and comorbidities 
cHR adjusted by age at diagnosis and gender 
dHR adjusted by age at diagnosis, gender, number of drinks per day and study centre 
eHR adjusted by age at diagnosis, gender, ethnicity, education level, comorbidities and alcohol drinking status 
fTotal number includes 247 OC, OP, HP NOS primary HNC with 21 s primary cancer 
gMedian, interquartile range 
  
Table 5 Multivariate predictors of second primary specific cancer site among 4021 head and neck cancer (HNC) cases 
Subjectsa,b Second primary cancer All second primary cancer 
HNCc  n = 113 Lungd  n = 54 Othere n = 82 
sites combinedf,g n = 344 
 
 n %  HR 95% CI  HR 95% CI  HR 95% CI  HR 95% CI 
Demographics 
Age at diagnosis 
 
 
4008 
 
59 (52–67)h 
  
 
1.00 
 
 
0.98–1.02 
  
 
1.01 
 
 
0.98–1.04 
  
 
1.00 
 
 
0.98–1.02 
  
 
1.01 
 
 
1.00–1.02 
Missing 13 0.3             
Gender               
Men 3111 77.6  1.00   1.00   1.00   1.00  
Women 898 22.4  1.54 1.01–2.35  4.29 2.24–8.23  1.88 1.13–3.13  1.11 0.82–1.51 
Missing 12 0.3             
BMI               
Underweight 194 6.7 1.00  1.00  1.00  1.00  
Normal range 1676 57.6 0.67 0.27–1.71 0.84 0.11–6.57 0.50 0.15–1.70 0.79 0.40–1.58 
Overweight 794 27.3 0.46 0.16–1.29 0.91 0.11–7.81 0.52 0.14–1.89 0.65 0.32–1.35 
Obese 245 8.4 0.65 0.20–2.14 0.56 0.03–9.02 0.47 0.09–2.34 0.46 0.18–1.13 
Missing 1112 27.7         
Ethnicity           
Caucasian 2846 72.0 1.00  1.00  1.00  1.00  
Black 236 6.0 0.74 0.27–2.04 nc nc 0.28 0.04–2.05 0.47 0.21–1.06 
Asian 316 8.0 nc nc nc nc 0.11 0.01–0.78 1.48 0.36–6.06 
Other 556 14.1 1.00 0.57–1.78 0.37 0.09–1.54 0.52 0.20–1.30 0.63 0.39–1.01 
Missing 67 1.7         
Education           
Less than high school 2665 80.3 1.00  1.00  1.00  1.00  
College/high school graduate 653 19.7 0.49 0.27–0.91 0.52 0.22–1.23 0.70 0.38–1.28 0.59 0.39–0.82 
Missing 703 17.5         
Tumour characteristics 
Stage 
I–II 933 28.2 1.00  1.00  1.00  1.00  
III–IV 2374 71.8 1.02 0.65–1.61 1.46 0.71–3.02 0.99 0.57–1.72 1.30 0.98–1.74 
Missing 714 17.8         
Comorbidity           
No 440 52.4 1.00  1.00  1.00  1.00  
Yes 400 47.6 0.98 0.46–2.09 3.68 1.04–13.02 1.06 0.52–2.13 1.14 0.75–1.73 
Missing 3181 79.1         
Cigarette smoking           
Smoking status           
Never 392 10.0 1.00  1.00  1.00  1.00  
Former 964 24.5 1.23 0.58–2.62 0.77 0.21–2.74 0.53 0.25–1.14 1.05 0.66–1.68 
Current 2574 65.5 1.46 0.72–2.94 2.43 0.82–7.72 0.75 0.38–1.47 1.57 1.01–2.44 
Missing 91 2.3         
Years of smoking           
Never smokers 392 10.2 1.00  1.00  1.00  1.00  
B 20 387 10.1 0.98 0.39–2.45 nc nc 0.32 0.11–1.02 0.88 0.49–1.59 
[ 20 3057 79.7 1.49 0.75–2.97 2.20 0.75–6.75 0.73 0.38–1.42 1.44 0.94–2.21 
Missing 185 4.6         
Cigarettes per day           
Never smokers 392 10.2 1.00  1.00  1.00  1.00  
B 20 2439 63.5 1.32 0.66–2.66 1.56 0.52–4.69 0.69 0.36–1.36 1.28 0.83–1.98 
  
Table 5 (continued) 
Subjectsa,b Second primary cancer All second primary cancer 
HNCc  n = 113 Lungd  n = 54 Othere n = 82 
sites combinedf,g n = 344 
  
 
 n %  HR 95% CI  HR 95% CI  HR 95% CI  HR 95% CI 
[ 20 1011 26.3  1.57 0.74–3.31  2.59 0.83–8.12  0.62 0.29–1.32  1.58 1.00–2.50 
Missing 179 4.5             
Alcohol drinking 
Drinking status 
              
Never drinkers 558 14.1 1.00  1.00  1.00  1.00  
Former 1004 25.4 3.87 1.78–8.44 1.87 0.41–8.46 2.05 0.59–7.11 1.67 0.89–3.14 
Current 2383 60.4 2.24 1.06–4.74 1.63 0.36–7.30 2.12 0.62–7.28 1.65 0.89–3.06 
Missing 76 1.9         
Drinks per day               
Never drinkers 558 15.1 1.00  1.00  1.00  1.00  
B 1 2255 61.2 6.64 2.37–18.62 2.42 0.86–6.85 2.47 1.00–6.11 1.51 1.00–2.29 
[ 1 872 23.7 5.78 1.94–17.25 3.38 1.29–8.84 2.88 1.21–6.87 1.37 0.89–2.10 
Missing 336 8.4         
Text in bold indicates statistically significant risk factors 
CI confidence interval, HNC head and neck cancer, HR hazard ratio, nc not computable 
aNumber of subject and percentages is referred to all HNC sites together 
bTotal number of subject includes 39 patients with missing information on HNC site 
cHR adjusted by age at diagnosis, gender and alcohol drinking status 
dHR adjusted by age at diagnosis, gender and number of drinks per day 
eHR adjusted by age at diagnosis, gender, ethnicity and number of drinks per day 
fHR adjusted by age at diagnosis, gender, education level, ethnicity, number of drinks per day and study centre gTotal second primary cancer 
include 95 patients with missing information on second primary cancer site hMedian, interquartile range 
 
Discussion 
 
In this large multicentre study, we evaluated the prognostic significance of demographic, lifestyle, and clinical char- 
acteristics on recurrence and occurrence of SPC. With a median follow-up of 2 years, recurrences occurred in 29% of the 
study patients, while SPCs in 9%, with the majority in the HNC region followed by cancers of lung. The inci- dence of 
recurrences was associated to the primary tumour staging in patients with oral cavity and oropharyngeal cancers. 
Compared to men, female patients with laryngeal cancer appeared to have a reduced risk of cancer recurrence. With 
respect to SPCs, female patients with oropharyngeal cancers appeared to have a higher risk than males. Advanced age and 
high alcohol consumption were risk factor for SPC among patients with laryngeal cancer, while belonging to the Asian 
ethnic group was protective. High tumour stage was associated with higher risk of recurrence among patients with oral 
cavity and oropha- ryngeal cancers, which is in agreement with other studies [16, 17]. In addition, former alcohol 
consummation was associated with lower risk of recurrence in patients with oral cavity cancer, which is not in line with 
our previous study [7], conducted on a smaller sample of patients with cancer recurrence. In this study, we did not 
investigate established factors associated with recurrence, such as human papillomavirus (HPV) status, and diet [17] 
because information on these variables was not available. A recent large study examined the prognostic utility of HPV 
biomarkers among head and neck squamous cell carcinoma cancer across different global regions, using centralized testing 
and controlling for other risk factors [18]. Tumour p16 and HPV16 DNA positivity were strong biomarkers for improved 
survival among oropharyngeal squamous cell cancer, but their prognostic utility was not as clear among non-
oropharyngeal head and neck squamous cell carcinoma cancer. 
Several epidemiologic studies have examined the asso- ciation between lifestyle habits such as smoking tobacco and 
consuming alcohol, and SPC in patients with HNC  [19, 20]. In our study alcohol, but not tobacco, was a sig- nificant risk 
factor for SPC development. These results are in line with the large body of evidence regarding alcohol intake and SPC risk 
in patients with HNC. Our previous multicentre study conducted in Italy on 117 HNC patients with SPC reported no 
significant association for smoking habits, though the risk for developing SPC increased with the increasing years of 
smoking ([ 40) [7]. Subjects from this study were also included in our current analyses [7]. In a recent study including 
nearly 1000 patients who were treated only in single hospital in South Korea, the reported risk factors for SPC in head and 
neck squamous-cell car- cinoma patients included the index alcohol consumption other than tumour site and patient age 
[21]. Our results are also consistent with those from a large study in 5 centres from South Europe, which reported a strong 
  
association between alcohol consumption and the risk of developing a SPC of the upper aerodigestive tract (UADT) among 
male patients with laryngeal or hypopharyngeal carcinoma [22]. A systematic review and meta-analysis of existing data 
from observational studies on the strength of the associa- tion of alcohol drinking with SPC risk in patients with UADT 
reported an increased risk of UADT SPCs, UADT and lung cancers, and for any SPCs [20]. Moreover, two studies 
investigated the association between SPC and continued alcohol consumption after UADT tumour diag- nosis, reporting not 
consistent results [23, 24]. However, since information on alcohol consumption after diagnosis is unknown, it was not 
possible to investigate this associ- ation in our study. Smoking is the most important risk factor for developing HNC [25, 
26]. Thus, it may seem surprising that it does not increase the risk of SPC after HNC as well. We hypothesize that some of 
the subjects with primary HNC might have stopped using tobacco after diagnosis of the first primary tumour, resulting in a 
decrease in the risk of tobacco-related SPCs [27]. There is another consideration. Patients who continue smoking after 
cancer diagnosis experience a consistent increase in risk of death compared with cancer patients who do not smoke after a 
cancer diagnosis [28], while persistent alcohol use did not affect survival [29]. 
The most obvious strength of this study was the large number of participants, which included HNC patients from three 
continents. Due to the large sample size, we were able to evaluate the risk of recurrence or recurrence by HNC subsites 
adjusting for multiple factors. Another strength is the detailed information about intensity and duration of pre-diagnosis 
tobacco and alcohol use. Limitations in our study are the lack of information on HPV status when exploring the recurrence 
of patients with oropharyngeal cancer since the risk of recurrence is lower in HPV-related than HPV-unrelated 
oropharyngeal squamous cell cancer [18]. Moreover, we did not have data on lifestyle changes after cancer diagnosis over 
time, which may have affected the prognosis. It was also not possible to investigate the influence of the persistence of 
tobacco and alcohol use in the appearance of SPC. Lastly, short follow-up period is another limitation, as one participating 
study had a median follow-up time lower than 2 years, though approximately 
35 to 55% of patients with HNC use to experience locoregional recurrence or distant metastasis within 2 years of initial 
diagnosis [8, 30, 31]. 
In summary, this large epidemiologic study investigated the association between demographics and lifestyle-related risk 
factors for HNC with recurrence and SPC development in HNC patients across continents. Tumour stage (both for oral 
cavity and oropharynx) and male gender (larynx only) were positive predictors of cancer recurrence in HNC patients. 
Predictors of SPC were advanced age, Asian ethnicity and alcohol among laryngeal cancer cases, and female gender for 
oropharyngeal and HNC overall. It would be important to collect information on tobacco use, alcohol consumption, diet 
habits, and other exposures in the interval between the first tumour and the occurrence of recurrence or SPC, to better 
define their role in reducing cancer recurrence or SPCs. 
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